“Challenging the Status Quo in Hereditary Hemorrhagic Telangiectasia” (Virtual Event)

Hanny Al-Samkari, MD

The Peggy S. Blitz Endowed Chair in Hematology / Oncology

Massachusetts General Hospital, Harvard Medical School

Dr. Hanny Al-Samkari is the Peggy S. Blitz Endowed Chair in Hematology/Oncology at the Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. He is a classical hematologist and NIH-funded clinical investigator and clinical trialist. He also serves as Co-Director the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence. His clinical and research interests are in hemostasis, thrombosis and hemolysis, with focuses in HHT, thrombocytopenias, and hemolytic anemias. As a clinical investigator, Dr. Al-Samkari is an internationally recognized expert in the clinical development of novel therapeutics for these disorders and serves as the lead principal investigator for multiple ongoing clinical trials. He is the emeritus Executive Editor of Hematology: The ASH Education Program and a current Associate Editor of the Journal of Thrombosis and Haemostasis. He has published over 170 peer-reviewed manuscripts. His original research has been featured in The New England Journal of Medicine, The Lancet, Annals of Internal Medicine and Blood, among other top peer-reviewed journals in hematology and medicine.

Join Meeting!

Objectives

• Appraise the diagnosis and clinical manifestations of hereditary hemorrhagic telangiectasia.
• Assess the risk of iFGF23-induced hypophosphatemia and osteomalacia caused by certain intravenous iron formulations.
• Apply safe and appropriate intravenous iron formulations for patients with HHT and other chronic bleeding disorders.

Faculty Disclosure:

Dr. Al-Samkari has indicated he has the following relevant financial relationships with commercial interests:

• Consultant – Agios, Amgen, Inc., Alnylam, Alpine, argenx, Pharmacosmos, Novartis Corporation Pharmaceuticals, Sobi, Sanofi S.A.
• Grant or research support – Agios, Amgen, Inc., Novartis Corporation Pharmaceuticals, Sobi, Vaderis

Planning Committee Disclosure:

Dr. Lekakis has indicated that he has no relevant financial relationships with commercial interests.

Target Audience

Primary care physicians.

Accreditation

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.   Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.”